Abstract |
The aim of this study was to describe the effects of sodium- glucose co-transporter 2 ( SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, CENTRAL, EMBASE and ClinicalTrials.gov were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to May 20, 2017. A total of 62 studies, comprising 34 941 patients, were included. Any of the SGLT2 inhibitors ( empagliflozin, canagliflozin, dapagliflozin, tofogliflozin, luseogliflozin or ipragliflozin) significantly decreased SUA levels compared with control (total weighted mean difference [WMD] -37.73 μmol/L, 95% CI [-40.51, -34.95]). Treatment with empagliflozin resulted in a superior reduction in SUA (WMD -45.83 μmol/L, 95% CI [-53.03, -38.63]). The effect persisted during long-term treatment. Dapagliflozin decreased SUA in a dose-dependent manner (from 5 to 50 mg, P = .014). In subgroup analyses, greater reductions could be observed during the course of early diabetes and the SUA-lowering effect was abolished in patients with chronic kidney disease (estimated glomerular filtration rate <60 mL/min per 1.73 m2 ). The effect of SGLT2 inhibitors on SUA reduction suggests that this class of drugs might be beneficial for diabetic patients with hyperuricaemia.
|
Authors | Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 20
Issue 2
Pg. 458-462
(02 2018)
ISSN: 1463-1326 [Electronic] England |
PMID | 28846182
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | © 2017 John Wiley & Sons Ltd. |
Chemical References |
- Benzhydryl Compounds
- Blood Glucose
- Glucosides
- Hypoglycemic Agents
- Membrane Transport Modulators
- SLC5A2 protein, human
- Sodium-Glucose Transporter 2
- dapagliflozin
- Uric Acid
- empagliflozin
|
Topics |
- Benzhydryl Compounds
(therapeutic use)
- Blood Glucose
(analysis)
- Diabetes Mellitus, Type 2
(blood, complications, drug therapy, metabolism)
- Glucosides
(therapeutic use)
- Humans
- Hyperglycemia
(prevention & control)
- Hyperuricemia
(blood, complications, drug therapy)
- Hypoglycemia
(prevention & control)
- Hypoglycemic Agents
(therapeutic use)
- Membrane Transport Modulators
(therapeutic use)
- Randomized Controlled Trials as Topic
- Sodium-Glucose Transporter 2
(metabolism)
- Uric Acid
(blood)
|